We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 178

New CMS Guidance for ADLT Lab Tests and ADLT Application Released
  • Reed Smith LLP
  • USA
  • April 6 2018

CMS is still rolling out policies and procedures to fully implement the major clinical laboratory payment reforms mandated by the Protecting Access to


House Panel Approves Off-Label Communication, OTC Monograph User Fee, Good Samaritan Health Professionals Bills
  • Reed Smith LLP
  • USA
  • January 23 2018

The House Energy and Commerce Health Subcommittee voted to approve the following health policy bills on January 18, 2017


OIG Report Assesses Accuracy of Manufacturer-Reported Medicaid Rebate Program Data
  • Reed Smith LLP
  • USA
  • December 21 2017

The OIG recently issued a report evaluating the accuracy of pharmaceutical manufacturer-reported Medicaid drug rebate program data, including pricing


Congressional Hearings Focus on Health Policy Issues
  • Reed Smith LLP
  • USA
  • November 29 2017

A number of Congressional panels have scheduled or held recent hearings on health policy issues, including the following


OIG Wants CMS to Track Medicare Costs from Device Failures
  • Reed Smith LLP
  • USA
  • October 27 2017

A recent Office of Inspector General (OIG) report suggests that the lack of medical device-specific information on Medicare claim forms complicates


House Energy & Commerce Committee Unanimously Approves FDA Reauthorization, Public Health Bills
  • Reed Smith LLP
  • USA
  • June 15 2017

On June 8, 2017, the Energy and Commerce Committee voted unanimously to approve an amended version of HR 2430, the FDA Reauthorization Act (FDARA) of


OIG Targets Additional MedicareMedicaid Policy Areas for Review
  • Reed Smith LLP
  • USA
  • June 15 2017

The OIG has added 18 reviews to its FY 2017 Work Plan - most of which target CMS programs, with a particular emphasis on prescription drug policies


President Trump’s Proposed FY 2018 Budget Spares Medicare, But Calls for Deep Medicaid Cuts & FDA User Fee Hikes
  • Reed Smith LLP
  • USA
  • June 1 2017

President Trump has released his FY 2018 budget proposal, which the Administration dubs "A New Foundation for American Greatness." The proposed


Congressional Panels Tackle FDA Reauthorization Act and Other Health Policy Issues
  • Reed Smith LLP
  • USA
  • May 12 2017

On May 11, 2017, the Senate on Health, Education, Labor, and Pensions (HELP) Committee approved S 934, a bill extend Food and Drug Administration


Congressional Panels Examining Pharmaceutical Distribution Systems, FDA Drug User Fees
  • Reed Smith LLP
  • USA
  • March 21 2017

Two Congressional committees are holding hearings this week on FDA user fees: a March 21 Senate Health, Education, Labor, and Pensions Committee